Lipopolysaccharide, method for producing lipopolysaccharide, and lipopolysaccharide formulation

A genetically modified bacterium, NITE BP-03562, addresses the industrial scalability and cost issues of LMM-LPSp production by producing high-purity LMM-LPSp with superior biological activity, suitable for various applications.

JP2024156505AActive Publication Date: 2024-11-06杣源一郎 +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2023071020
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-24
Publication Date
2024-11-06
Estimated Expiration
2043-04-24

AI Technical Summary

Technical Problem

Existing methods for producing high-purity low molecular weight Pantoea agglomerans lipopolysaccharide (LMM-LPSp) are costly and impractical for industrial scale due to the presence of high molecular weight types (HMM-LPSp) despite advancements like gel filtration and culture methods.

Method used

A bacterium with accession number NITE BP-03562 is used to produce lipopolysaccharide, characterized by genetic modifications, allowing for high-purity LMM-LPSp production at low cost, eliminating the need for costly purification processes.

Benefits of technology

The modified bacterium produces LMM-LPSp with enhanced biological activity, suitable for incorporation into pharmaceuticals, veterinary drugs, cosmetics, foods, and other products, offering improved immune activation capabilities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156505000001_ABST
    Figure 2024156505000001_ABST
Patent Text Reader

Abstract

To produce a high-purity low-molecular-weight lipopolysaccharide at a low cost by a deposited bacterium that produces the high-purity low-molecular-weight lipopolysaccharide.SOLUTION: Provided are: a lipopolysaccharide obtained from a deposited bacterium obtained by causing a change in genetic information of conventional Pantoea agglomerans; a method for producing the lipopolysaccharide obtaining the lipopolysaccharide from the deposited bacterium; and a liposaccharide formulation containing the liposaccharide such as a pharmaceutical, an animal pharmaceutical, a quasi-drug, a cosmetic, a food, a functional food, a feed, a fertilizer or a bathing agent.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to lipopolysaccharide, an immunostimulant that is safe to add to pharmaceuticals, quasi-drugs, cosmetics, foods, functional foods, feed, fertilizers, bath additives, and other products for animals including humans and plants, a method for producing said lipopolysaccharide, and a lipopolysaccharide blend containing said lipopolysaccharide. [Background technology]

[0002] Lipopolysaccharide (hereinafter sometimes referred to as LPS) is a complex compound consisting of lipids and sugars that is present in the outer membrane surrounding the peptidoglycan of the cell wall of gram-negative bacteria. Its basic structure is made up of three components: lipid A, which has a specific lipid; an oligosaccharide called a core polysaccharide covalently bound to the lipid A; and O-antigen polysaccharide, which has a diverse structure depending on the bacterium. O-antigen polysaccharides generally have a certain structure of several sugars that are repeatedly linked together as units, but the number of repetitions varies, and as a result, the molecular weight is non-uniform (Non-Patent Document 1).

[0003] LPS has a variety of pharmacological actions, including preventive effects against the onset of diabetes, suppressive effects against dyslipidemia, suppressive effects against atopic dermatitis, and an adjuvant effect that enhances the efficacy of vaccines (Non-Patent Document 2). We found that LPS (LPSp) from Pantoea agglomerans isolated from wheat was highly effective when administered orally (Non-patent Document 1).

[0004] Analysis of LPSp revealed the existence of low molecular weight forms (LMM) and high molecular weight forms (HMM). We then introduced a gel filtration method using deoxycholic acid and succeeded in separating LPSp into LMM-LPSp and HMM-LPSp. It was confirmed that this LMM-LPSp had tumor necrosis factor (TNF)-inducing activity, an indicator of immune activation, approximately 10 times higher than that of the original LPS when administered intravenously (Patent Document 1, Non-Patent Document 3).

[0005] However, although the gel filtration method using deoxycholic acid has been performed on a laboratory scale, it has been difficult to industrialize it and is very costly, making it impractical. To solve this problem, we developed a culture method in which LMM-LPSp is contained in a larger amount than HMM-LPSp (Patent Document 2). [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Patent No. 4043533 [Patent Document 2] JP 2022-160938 A [Patent Document 3] Patent No. 5511112 [Non-patent literature]

[0007] [Non-Patent Document 1] I. Lerouge et al., “O-antigen structural variation: mechanisms and possible roles in animal / plant-microbe interactions”, FEMS Microbiology Reviews, 2002.03, 26(1), p.17-47 [Non-Patent Document 2] C. Kohchi et al., “Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for health care based on macrophage network theory”, Journal of Bioscience and Bioengineering, 2006.12, 102(6), p.485-496 [Non-Patent Document 3] T. Kadowaki et al., “Induction of nitric oxide production in RAW264.7 cells under serum-free conditions by O-antigen polysaccharide of lipopolysaccharide”, ANTICANCER RESEARCH, 2013.07, 33(7), p.2875-9 Summary of the Invention [Problem to be solved by the invention]

[0008] However, even the culture method of Patent Document 2 still contained a significant amount of HMM-LPSp. If bacteria capable of producing high-purity LMM-LPSp existed, it would be possible to easily produce high-purity LMM-LPSp, and ideal LPS could be produced at low cost. [Means for solving the problem]

[0009] The lipopolysaccharide of the present invention is characterized in that it is obtained from a bacterium having accession number NITE BP-03562.

[0010] The method for producing lipopolysaccharide of the present invention is characterized in that lipopolysaccharide is obtained from the bacterium having the accession number NITE BP-03562.

[0011] The lipopolysaccharide formulation of the present invention is characterized in that it contains the above-mentioned lipopolysaccharide.

[0012] The lipopolysaccharide formulation is preferably a pharmaceutical product, a veterinary drug, a quasi-drug, a cosmetic product, a food product, a functional food product, a feed, a fertilizer, or a bath additive. Effect of the Invention

[0013] The lipopolysaccharide of the present invention is obtained from a bacterium (deposited bacterium) obtained by inducing changes in the genetic information of conventional Pantoea agglomerans, and therefore an ideal low molecular weight can be obtained without using a special gel filtration method or the like. Furthermore, the biological activity of the lipopolysaccharide of the present invention is higher than that of conventional lipopolysaccharides. The lipopolysaccharide of the present invention is a novel lipopolysaccharide having a molecular weight and sugar chain composition different from those of conventional lipopolysaccharides. Furthermore, since the lipopolysaccharide of the present invention is liberated from the deposited bacterium by heating, it can be prepared at low cost using the preparation methods for livestock feed materials, food materials, and cosmetic materials that omit the purification process that has been used so far. [Brief description of the drawings]

[0014] [Figure 1] FIG. 1 is an electrophoretic image showing the molecular weight of the lipopolysaccharide of the present invention. [Diagram 2] FIG. 1 shows the NO production activity of the lipopolysaccharide of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Preferred embodiments of the present invention will now be described in detail. EXAMPLES

[0016] 1. Creation of Pantoea agglomerans Strain IG1-47 (1-1) Obtaining mutants of Pantoea agglomerans by mutagen treatment A part of a colony of Pantoea agglomerans (IG1 strain) was scraped off and inoculated on LB (Luria-Bertani) agar medium and cultured overnight in a thermostatic chamber at 35°C. One of the colonies was cultured in sterilized LB medium (50mL scale in a baffled flask) for 16 hours (35°C, 170 rpm). The culture was then centrifuged (3000 rpm x 5 min) to collect the bacteria and suspended in 50mM potassium phosphate solution (pH 6.0). The number of bacteria was adjusted to 1x10^7 / mL, and 1mL of the culture was dispensed into a 1.5mL tube. A solution of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) was added to this tube as a mutagen to a final concentration of 100μg / mL and gently mixed. The tube was then incubated at 37°C for 0.5, 1, 1.5, 2, 3, and 4 hours. After each time, the bacteria were collected by centrifugation and washed twice with 50 mM potassium phosphate solution (pH 6.0) (suspended, centrifuged, the supernatant discarded, and resuspended). The cell suspension was plated on LB agar medium and incubated overnight at 37°C, and the number of colonies was counted the next day (Table 1).

[0017] The colonies treated with MNNG for 3 and 4 hours, which were 99.9% dead, were visually evaluated for colony shape. Strains that formed larger, whiter, and less shiny colonies than those treated with MNNG were preferentially selected. As a result, the following candidate mutant strains were obtained: (1) 108 large, white, and less shiny colonies; (2) 61 yellow, smooth colonies; (3) 3 yellow-rough colonies; (4) 6 pale yellow-smooth colonies; (5) 36 milky-smooth colonies; and (6) 2 milky-rough colonies.

[0018] [Table 1]

[0019] (1-2) Screening of isolated strains with high LPS content 108 strains (No. 1 to No. 108) were cultured on LB plates and the cells were harvested. The wet cell weight was measured, and 1 mL of a 10 mg / mL water suspension was prepared. After heating at 90°C for 20 minutes, the suspension was centrifuged and the supernatant was used as a hot water extract. The amount of LPS contained in this solution was measured as a Limulus value (a value obtained by the Limulus test, a conversion value of LPS produced by the control standard endotoxin E. coli UKT-B) using a toxinometer (Fujifilm Wako Pure Chemical Industries, Ltd.). Five strains with high LPS content (No. 11, 25, 32, 41, and 47) were selected as candidate strains.

[0020] The untreated (parent strain) and five candidate strains were cultured in LB medium (50 mL scale in a baffled flask) for 16 hours (35°C, 170 rpm) (n=3). After culture, the bacteria were harvested, the wet cell weight was measured, a 10 mg / mL water suspension was prepared, and a hot water extract was obtained. The amount of LPS contained in the hot water extract was calculated using the Limulus value.

[0021] As a result, the LPS content per wet cell weight of the candidate strains No. 11 and No. 47 was 20 mg / g or more, compared with an average of 11.72 ± 1.28 mg / g for the parent strain, indicating that both candidate strains No. 11 and No. 47 are excellent strains in LPS production.

[0022] One method for adjusting LPS is to use disrupted bacterial cells (Patent Document 3). Since this uses fermentation culture medium (both the bacterial cells and the culture medium contain LPS) as the material, it is desirable to evaluate the amount of LPS produced per culture medium. Thus, the parent strain and candidate strains No. 11 and No. 47 were cultured, and the amount of LPS produced per 42.5 mL of culture medium was compared. No. 47 had the highest amount of LPS produced by the bacterial cells, and also had the highest amount of LPS produced by the total amount of the bacterial cells and culture supernatant combined (Table 2).

[0023] [Table 2]

[0024] (1-3) NO production activity induction ability of candidate strains The biological activity of LPS was evaluated by its ability to induce nitric oxide (NO), a cell signaling substance in macrophages that is also an antiviral and antibacterial substance.

[0025] A culture medium containing a double concentration of the sample was added to RAW264.7 cells (1.6 x 10^5 cells / well), which are cultured cells of peripheral blood monocytic lineage, and cultured for 24 hours. The amount of NO production was measured by measuring the concentration of its metabolic product, nitrite, using Griess reagent. The concentration of LPS (LPSp: Funakoshi, mac0001) derived from Pantoea agglomerans was expressed as dry weight, and the LPS concentration of the sample was compared by Limulus measurement. Results: The NO production of strain No. 47 was found to be higher than that of strain No. 11 and the parent strain (Table 3).

[0026] [Table 3] *: Significantly higher than the parent strain and No. 11 by Tukey's multiple comparison (n=4, P<0.001).

[0027] As a result of the screening, strain No. 47 was selected as a candidate for a high LPS content strain based on the LPS recovery amount and NO production activity, named IG1-47, and deposited (accession number NITE BP-03562).

[0028] 2. Characterization of LPS from Pantoea agglomerans strain IG1-47 (IG1-47 LPSp) (2-1) Cultivation of Pantoea agglomerans strain IG1-47 The parent strain Pantoea agglomerans (IG1 strain) and IG1-47 strain were cultured in LB medium in a baffled flask at a 50 mL scale for 16 hours (35°C, 170 rpm). After cultivation, the culture solution was centrifuged to harvest the bacteria (3.5 krpm, 30 minutes). The supernatant was collected in a separate container. The wet cell weight of the harvested bacteria was measured. The wet cell recovery amount of IG1-47 strain was 273.4 mg ± 3.6 mg, the average and standard deviation of three cases. A 10 mg / mL water suspension was prepared from this wet cell. 0.5 mL of the suspension was heat-treated at 90°C for 30 minutes. After heat treatment, it was ultrasonicated (10 minutes) and stirred using a vortex mixer. The suspension was diluted with water and the limulus value was measured using a toxinometer (FUJIFILM Wako Pure Chemical Industries, Ltd.).

[0029] (2-2) Purification of lipopolysaccharide from Pantoea agglomerans IG1-47 strain A part of the colony of IG1-47 strain was scraped off and spread on LB agar medium and cultured overnight in a thermostatic chamber at 35°C. One colony was added to 10 mL of sterilized LB medium and pre-cultured at 35°C with shaking at 170 rpm. 0.05 mL of the pre-culture liquid was placed in a 250 mL baffled flask containing 50 mL of LB medium and cultured overnight with shaking at 35°C. After culture, the culture liquid was transferred to a 50 mL centrifuge tube and centrifuged at 3500 rpm (KUBOTA Model 5220 tabletop centrifuge) to recover 276.1 mg of wet cells. Lipopolysaccharide purification from the wet cells of IG1-47 strain was performed according to the method of Westphal et al. That is, distilled water was added to 276.1 mg of wet cells to make the wet cells 100 mg / ml. The bacteria were suspended, and the same volume of 90% phenol was added to this liquid and stirred at 65°C to 70°C for 15 minutes. The liquid was then cooled to 4°C and centrifuged at 3500 rpm. 1 mL of the upper aqueous layer was collected in a separate container, and the remaining phenol layer and the same amount of distilled water as the aqueous layer collected in the middle layer were added, and the mixture was stirred again at 65°C to 70°C for 10 minutes to re-extract lipopolysaccharide. The liquid was then cooled to 4°C and centrifuged. 2 mL of the second aqueous layer was combined with the first aqueous layer, diluted 10 times with distilled water, and low molecular weight substances including phenol were removed using a centrifugal ultrafiltration filter with a molecular weight cutoff of 10,000. 3 mL of this ultrafiltrated inner liquid was further treated with a nuclease (benzonase) (20 U / ml). Nucleic acids decomposed by ultrafiltration were removed. The inner liquid was treated with a protease (proteinase K) (200 μg / ml), followed by phenol extraction, and then the aqueous layer was used to remove phenol using a centrifugal ultrafiltration filter with a molecular weight cutoff of 10,000. 4 mL of the inner liquid was collected. This concentrated solution was used as a purified lipopolysaccharide solution of IG1-47 strain Pantoea agglomerans (IG1-47 LPSp). This solution was freeze-dried and the dry weight was measured. The dry weight of the purified lipopolysaccharide was 2.0 mg.

[0030] (2-3) Measurement of molecular weight of lipopolysaccharide IG1-47 LPSp The molecular weights of IG1-47 LPSp (0.1 μg / lane) and chromatographically purified LMM-LPSp (0.1 μg / lane) were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using tricine (20% gel, SDS-PAGE). After electrophoresis, silver staining was performed using a silver staining kit (Cat291-50301, Silver Stain II Kit, Fujifilm Wako Pure Chemical Industries, Ltd.) to visualize the lipopolysaccharide molecules. Since LPS is a glycolipid, its behavior differs from that of commonly used protein molecular weight markers, glycolipids with known molecular weight sizes were used as molecular weight markers (Salmonella minnesota Rb2 LPS (molecular weight: 3878 Da) (0.3 μg / lane), Salmonella minnesota Rd2 LPS (molecular weight: 2777 Da) (0.3 μg / lane)).

[0031] The results are shown in Figure 1. Lane (3) shows one band for IG1-47 LPSp. Lane (4) shows two bands for chromatographically purified LMM-LPSp of the parent strain LPS.

[0032] The band position of IG1-47 LPSp was slightly lower than the lower band of the two bands of chromatographically purified LMM-LPSp. The exact molecular weight is unknown, but it is estimated to be about 4000 Da.

[0033] (2-4) Measurement of the composition of lipopolysaccharide IG1-47 LPSp 10 mg of purified IG1-47 LPSp was weighed out on an electronic balance and added to a 15 mL conical tube. Distilled water for injection was added to prepare a 2.0 mg / mL aqueous solution of IG1-47 LPSp.

[0034] (2-4-1) Nucleic acid content measurement To measure the nucleic acid concentration, 50 μL of 2.0 mg / mL IG1-47 LPSp aqueous solution was added to 950 μL of distilled water to make 100 μL / mL, and the spectrum was measured in the range of 200 nm to 340 nm using a plate reader. The nucleic acid content was measured by multiplying the value obtained by subtracting the absorbance value at 320 nm from the absorbance value at 260 nm by 50 μg / mL. No peak was observed at the absorption wavelength of 260 nm. The estimated nucleic acid content was 5.6% based on the value obtained by subtracting the absorbance value at 320 nm from the absorbance value at 260 nm. Since no peak was observed at 260 nm, the amount of nucleic acid was less than the calculated value, and since the absorbance due to the turbidity of IG1-47 LPSp was included, the estimated nucleic acid content was estimated to be less than 5.6% (Table 4).

[0035] (2-4-2) Protein content measurement Protein content was determined by the Lowry method. Bovine serum albumin was measured as a protein standard, and the protein content of IG1-47 LPSp was determined to be 0.75% in terms of bovine serum albumin (Table 4).

[0036] (2-4-3) Measurement of neutral sugar content (phenol-sulfuric acid method) The neutral sugar content was measured by the phenol-sulfuric acid method using glucose as a standard. The measured value was 40.6%. The measured value of chromatographically purified LMM-LPSp was 34.0% (Table 4).

[0037] [Table 4]

[0038] (2-4-4) Monosaccharide composition analysis (thermal decomposition method) The monosaccharide composition was analyzed by hydrolysis and then analyzed by HPLC as ABEE derivatives. As a result, five types of sugars were measured in IG1-47 LPSp (Table 5).Five types of sugars were also measured in LMM-LPSp (Table 5).

[0039] Comparing the ratio of each sugar (GlcNAc defined as 2) between IG1-47 LPSp and LMM-LPSp, IG1-47 LPSp had approximately 1 more glucose (Glc) and 1 more rhamnose (Rha). These results demonstrated that there was a difference in the ratio of monosaccharide composition between IG1-47 LPSp and LMM-LPSp.

[0040] [Table 5] *: Relative ratio when GlcNAc is set to 2

[0041] (2-4-5) Measurement of immunostimulatory activity 1 (NO production from RAW264.7 cells) After adding LPS to RAW264.7, a mouse macrophage cell line, the production of nitric oxide (NO) from the cells was measured using the concentration of nitrite, an NO metabolite, in the culture medium as an index. RAW264.7 was purchased from ATCC (No. TIB-71). LPSp (parent strain LPS, mac0001) was used as a control. RAW264.7 cells were harvested from the culture flask by pipetting, and the cell concentration was adjusted to 1.6 x 10^6 cells / ml with culture medium (RPMI1640 medium containing 10% fetal bovine serum, 100 U / ml penicillin, and 100 μg / ml streptomycin). 100 μl of the cell suspension (1.6 x 10^5 cells / 100 μl) was transferred to each well of a 96-well flat-bottom plate, and used in the test after 3 hours. IG1-47 LPSp was adjusted to 2000 ng / ml. Further, five 10-fold serial dilutions were made to prepare samples to be added to the wells containing the cells. At the same time, LPSp and chromatographically purified LMM-LPSp were also tested. 100 μl of each sample was added to each well of a 96-well flat-bottom plate to which cells had already been added. The cells were cultured for 24 hours at 37°C in a 5% carbon dioxide incubator, and after the culture was completed, 100 μl of the supernatant was collected in a separate 96-well plate. The amount of nitrite, a metabolite of nitric oxide, in the culture medium was measured using Griess reagent according to standard methods.

[0042] [Measurement results] IG1-47 LPSp was found to have significantly higher NO production activity than chromatographically purified LMM-LPSp and LPSp (Figure 2).

[0043] (2-4-6) Measurement of immunostimulatory activity 2 (TNFα production in THP-1 cells) TNFα production was measured by ELISA after addition of LPS to THP-1, a cultured human monocytic leukemia cell line. THP-1 (JCRB0112.1) was purchased from the JCRB Cell Bank. LPSp (parent strain LPS, mac0001) and chromatographically purified LMM-LPSp were used as controls.

[0044] THP-1 cells were collected from the culture flask by pipetting, and the cell concentration was adjusted to 8×10^5 cells / ml with culture medium (RPMI1640 medium containing 10% fetal bovine serum, 100 U / ml penicillin, and 100 μg / ml streptomycin). 100 μl of the cell suspension (8×10^4 cells / 100 μl) was transferred to each well of a 96-well flat-bottom plate. IG1-47 LPSp was adjusted to 2000 ng / ml. Five 10-fold serial dilutions were then made to prepare samples to be added to the wells containing the cells. At the same time, LPSp and chromatographically purified LMM-LPSp were also tested. 100 μl of each sample was added to each well of the 96-well flat-bottom plate to which the cells had already been added. The cells were cultured for 24 hours at 37°C in a 5% carbon dioxide incubator, and the supernatant was collected in a plastic tube after the culture was completed. The TNFα concentration in the culture medium was measured according to the measurement method of the TNFα kit.

[0045] [Measurement results] IG1-47 LPSp induced significantly higher TNFα production, up to 5-fold, at a dose of 0.1 ng / mL compared to chromatographically purified LMM-LPSp (Table 6).

[0046] [Table 6] *: There was a significant difference in the amount of TNFα produced by IG1-47 LPSp between LMM-LPSp and LPSp (P<0.05).

[0047] These results demonstrate that IG1-47 LPSp has a different structure from conventional LMM-LPSp, has high innate immune activation ability, and can be produced at low cost. The obtained lipopolysaccharide is useful when incorporated into pharmaceuticals, veterinary drugs, quasi-drugs, cosmetics, foods, functional foods, feed, fertilizers, bath additives, and the like.

Claims

1. A lipopolysaccharide characterized in that it is obtained from a bacterium having accession number NITE BP-03562.

2. A method for producing lipopolysaccharide, comprising obtaining lipopolysaccharide from a bacterium having accession number NITE BP-03562.

3. A lipopolysaccharide formulation comprising the lipopolysaccharide according to claim 1.

4. The lipopolysaccharide formulation according to claim 3, characterized in that the lipopolysaccharide formulation is a pharmaceutical product, a veterinary drug, a quasi-drug, a cosmetic product, a food product, a functional food product, a feed, a fertilizer, or a bath additive.

Citation Information

Patent Citations

  • Low-molecular weight lipopolysaccharide

    JP1996198902A

  • Vaccine pharmaceutical composition for transdermal administration

    JP2016074654A

  • Allergy vaccine composition

    JP2016210771A

  • Fermentation and culture method, lipoprotein polysaccharide, fermentation extract, fermentation extract powder and compound thereof

    JP2022160938A

  • Lipopolysaccharide production method

    WO2021060127A1